Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Studying the role of dystrophin-associated proteins in influencing Becker muscular dystrophy disease severity.

van den Bergen JC, Wokke BH, Hulsker MA, Verschuuren JJ, Aartsma-Rus AM.

Neuromuscul Disord. 2015 Mar;25(3):231-7. doi: 10.1016/j.nmd.2015.01.002. Epub 2015 Jan 14.

PMID:
25633150
2.

Dystrophin levels and clinical severity in Becker muscular dystrophy patients.

van den Bergen JC, Wokke BH, Janson AA, van Duinen SG, Hulsker MA, Ginjaar HB, van Deutekom JC, Aartsma-Rus A, Kan HE, Verschuuren JJ.

J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):747-53. doi: 10.1136/jnnp-2013-306350. Epub 2013 Nov 29.

PMID:
24292997
3.

Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy.

van den Bergen JC, Schade van Westrum SM, Dekker L, van der Kooi AJ, de Visser M, Wokke BH, Straathof CS, Hulsker MA, Aartsma-Rus A, Verschuuren JJ, Ginjaar HB.

J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):92-8. doi: 10.1136/jnnp-2012-304729. Epub 2013 May 10.

PMID:
23667215
4.

Comprehensive gene-expression survey identifies wif1 as a modulator of cardiomyocyte differentiation.

Buermans HP, van Wijk B, Hulsker MA, Smit NC, den Dunnen JT, van Ommen GB, Moorman AF, van den Hoff MJ, 't Hoen PA.

PLoS One. 2010 Dec 13;5(12):e15504. doi: 10.1371/journal.pone.0015504.

Supplemental Content

Loading ...
Support Center